RGEN Quote, Financials, Valuation and Earnings

Masimo Corp. has a net margin of 6.71% compared to Repligen Corp.'s net margin of 15.01%. Repligen Corp.'s return on equity of 2.4% beat Masimo Corp.'s return on equity of 22.71%.

Repligen Corp. has a consensus price target of $185.72, signalling upside risk potential of 62.63%. On the other hand Masimo Corp. has an analysts' consensus of $178.60 which suggests that it could grow by 1.77%. Given that Repligen Corp. has higher upside potential than Masimo Corp., analysts believe Repligen Corp. is more attractive than Masimo Corp..

Repligen Corp. has a beta of 1.145, which suggesting that the stock is 14.545% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.291%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $197.9M, which are smaller than Masimo Corp. quarterly revenues of $412.5M. Repligen Corp.'s net income of $13.3M is lower than Masimo Corp.'s net income of $61.9M. Notably, Repligen Corp.'s price-to-earnings ratio is 132.10x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 8.75x versus 6.19x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical, Inc. has a net margin of 6.71% compared to Repligen Corp.'s net margin of -1.01%. Repligen Corp.'s return on equity of 2.4% beat Orthofix Medical, Inc.'s return on equity of -19.94%.

Repligen Corp. has a consensus price target of $185.72, signalling upside risk potential of 62.63%. On the other hand Orthofix Medical, Inc. has an analysts' consensus of $17.25 which suggests that it could grow by 47.44%. Given that Repligen Corp. has higher upside potential than Orthofix Medical, Inc., analysts believe Repligen Corp. is more attractive than Orthofix Medical, Inc..

Repligen Corp. has a beta of 1.145, which suggesting that the stock is 14.545% more volatile than S&P 500. In comparison Orthofix Medical, Inc. has a beta of 0.750, suggesting its less volatile than the S&P 500 by 25.028%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Orthofix Medical, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $197.9M, which are smaller than Orthofix Medical, Inc. quarterly revenues of $219.9M. Repligen Corp.'s net income of $13.3M is higher than Orthofix Medical, Inc.'s net income of -$2.2M. Notably, Repligen Corp.'s price-to-earnings ratio is 132.10x while Orthofix Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 8.75x versus 0.56x for Orthofix Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 6.71% compared to Repligen Corp.'s net margin of -417.92%. Repligen Corp.'s return on equity of 2.4% beat Plus Therapeutics, Inc.'s return on equity of --.

Repligen Corp. has a consensus price target of $185.72, signalling upside risk potential of 62.63%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $6.25 which suggests that it could grow by 2400%. Given that Plus Therapeutics, Inc. has higher upside potential than Repligen Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.145, which suggesting that the stock is 14.545% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $197.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Repligen Corp.'s net income of $13.3M is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Repligen Corp.'s price-to-earnings ratio is 132.10x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 8.75x versus 5.63x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of 6.71% compared to Repligen Corp.'s net margin of -0.2%. Repligen Corp.'s return on equity of 2.4% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.

Repligen Corp. has a consensus price target of $185.72, signalling upside risk potential of 62.63%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $29.59 which suggests that it could grow by 37.06%. Given that Repligen Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Repligen Corp. is more attractive than Tandem Diabetes Care, Inc..

Repligen Corp. has a beta of 1.145, which suggesting that the stock is 14.545% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.626, suggesting its more volatile than the S&P 500 by 62.563%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $197.9M, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Repligen Corp.'s net income of $13.3M is higher than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Repligen Corp.'s price-to-earnings ratio is 132.10x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 8.75x versus 1.43x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.